课题基金 / 基金详情

项目摘要

项目成果

Leonard Neckers的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We confirmed that alternatively spliced androgen receptor (lacking ligand binding domain with which Hsp90 interacts) interacts with and remains dependent on Hsp40 and Hsp70 for stability and transcriptional activity. Further, we showed that targeting the Hsp40/Hsp70 chaperone axis is a novel strategy to treat castration-resistant prostate cancer that has become resistant to standard ant-iandrogen therapy. (2) We identified a multichaperone complex in mitochondria comprised of Trap1, Hsp60 and mitochondrial Hsp70 as a regulator of oxidative phosphorylation and ATP synthase-mediated ATP production. Assembly of the multichaperone complex is sensitive to mitochondrial ATP level. We identified multiple subunits of ATP synthase and numerous electron transport chain components as Trap1 interactors (potential clients), and we demonstrated that Trap1 knockout leads to increased oxidative phosphorylation and a strong preference for glutamine as the primary carbon source for the TCA cycle. (3) We also demonstrated that Hsp70 inhibition blocked both heat-induced and Hsp90 inhibitor-potentiated HSF1 activation and transcriptional activity by causing the destabilization of HSF1. We showed that Hsp70 bound to both HSF1 monomers (inactive) and trimers (active). confirmed in vitro and in vivo activity of Hsp70 inhibitor on castrate resistant prostate, but demonstrated an early and profound effect on mitochondrial protein translation which leads to disruption of electron transport chain (ETC) complex I, with resultant collapse of the ETC. This outcome is phenocopied by a specific inhibitor of complex I. In both cases, disruption of mitochondrial respiration restores sensitivity to enzalutamide as long as residual wild type androgen is present. In vitro effects are reproducible in vivo and can be non-invasively imaged with hyperpolarized pyruvate MR spectroscopy (HP-MRSI).
期刊论文(66)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 2009-03
期刊: Anticancer research
影响因子: 2
作者: [F. Koga;K. Kihara;L. Neckers]
通讯作者: F. Koga;K. Kihara;L. Neckers
The therapeutic target Hsp90 and cancer hallmarks.
治疗靶标 Hsp90 和癌症标志。
DOI: 10.2174/138161213804143725
发表时间: 2013
期刊: Current pharmaceutical design
影响因子: 3.1
作者: [Miyata Y, Nakamoto H, Neckers L]
通讯作者: Neckers L
DOI: 10.1371/journal.pone.0141786
发表时间: 2015
期刊: PloS one
影响因子: 3.7
作者: [Prince TL, Kijima T, Tatokoro M, Lee S, Tsutsumi S, Yim K, Rivas C, Alarcon S, Schwartz H, Khamit-Kush K, Scroggins BT, Beebe K, Trepel JB, Neckers L]
通讯作者: Neckers L
DOI: 10.4155/fmc.13.88
发表时间: 2013-06
期刊: Future medicinal chemistry
影响因子: 4.2
作者: [Walton-Diaz A, Khan S, Bourboulia D, Trepel JB, Neckers L, Mollapour M]
通讯作者: Mollapour M
44
    Role of HSP90 Family Chaperone Proteins in Cellular Signal Transduction
    Post-translational modifications of Hsp90 that impact drug efficacy
    • 批准号:
      8937930
    • 项目类别:
    • 资助金额:
      $66.8万
    • 财政年份:
      --
    • 负责人:
      Leonard Neckers
    • 依托单位:
    Role of FH loss in development of HLRCC heriditary kidney cancer
    • 批准号:
      9556337
    • 项目类别:
    • 资助金额:
      $45.65万
    • 财政年份:
      --
    • 负责人:
      Leonard Neckers
    • 依托单位:
    Post-translational modifications of Hsp90
    • 批准号:
      10702456
    • 项目类别:
    • 资助金额:
      $43.32万
    • 财政年份:
      --
    • 负责人:
      Leonard Neckers
    • 依托单位:
    海外基金